As a part of the 2023 AQUA Registry renewal process, AUA asks practices to select their list of priority measures by February 17, 2023 using the following link.

This year, in order to establish CMS benchmarks and add more value to AQUA’s urology specific measures, we will be applying the following measures to ALL participating practices (Standard & MIPS subscription levels) across the AQUA Registry:

• AQUA16: Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease
• MUSIC4: Prostate Cancer: Active Surveillance/Watchful Waiting for Newly-Diagnosed Low-Risk Prostate Cancer Patients

We encourage you to review, validate and report (if applicable) the measures listed above.

These measures can be submitted to CMS in addition to other preferred measures. Please note, when CMS calculates your MIPS score, they will only use the six highest scoring measures. Therefore, reporting these additional measures will not negatively impact your MIPS score. However, it will help strengthen the AQUA Registry’s benchmarks and, potentially, yield you with more points for reporting on these measures in future performance years.

Test Measures:

Furthermore, AUA will be applying AUA01 (formerly AQUA18) and AUA02 (formerly MUSIC10), test measures, to a subset of AQUA Registry participants. Here is how these measures are changing from their former versions:

• *AUA01- The focus of AUA01 is to assess initial management/surveillance of patients with non-muscle invasive bladder cancer during the first 14 months post-TURBT, rather than focusing solely on early surveillance cystoscopy.
• *AUA02- The focus of AUA02 is to assess confirmatory biopsy within 24 months among newly diagnosed low-risk prostate cancer patients who are on active surveillance, rather than to focus on confirmation testing within 6 months of diagnosis.

* These test measures cannot be used for 2023 MIPS reporting

 The selection of these test measures (AUA01 and AUA02) will give the AUA enough data to prove, to CMS, that we have the necessary data elements needed to properly calculate these measures. The end goal is to put these forth, in the 2024 self-nomination cycle, for MIPS use. This objective can be accomplished only if a substantial number of AQUA practices use the measures.

If you have any questions on the selection of your priority measures, please contact us at AQUA@auanet.org